Marshall Wace North America’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Marshall Wace North America’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1,057	Closed	-$31K	–	1996
2018 Q4	$31K	Buy	+1,057	New	+$46.9K	﹤0.01%	1362
2017 Q2	–	Sell	-1,478	Closed	-$177K	–	1500
2017 Q1	$177K	Buy	+1,478	New	+$194K	﹤0.01%	924

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Marshall Wace North America's BLCM Position: Q1 2019 in Review

Marshall Wace North America sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2019, closing a stake of 1,057 shares — an estimated $31K sold.

Marshall Wace North America first reported a position in BLCM in Q1 2017 and held it in 2 quarters. The position peaked at $177K in Q1 2017. 94 funds tracked by Wall St. Rank hold BLCM as of Q1 2019.

Marshall Wace North America reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Marshall Wace North America sold 1,057 Bellicum Pharmaceuticals, Inc. shares in Q1 2019, an estimated $31K.
Marshall Wace North America first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2017 and held it in 2 quarters.
Marshall Wace North America's Bellicum Pharmaceuticals, Inc. position peaked at $177K in Q1 2017.
94 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.